Margien Boels is Investment Manager of BGV’s FIRST fund. BioGeneration Ventures’ FIRST Fund (Fonds InvesteringsRijpe Starters) is a pre-seed fund that finances pioneering scientists in The Netherlands who are active in the field of chronic diseases. FIRST supports leading scientists in these fields to transform their breakthrough discoveries into sustainable, innovative companies that can develop the products needed to improve patients’ lives.

In parallel, Margien is COO of FIRST’s portfolio company Phlox Therapeutics, where she drives strategic growth and operational excellence. Phlox develops a novel RNA-based therapeutic for rare cardiomyopathies.

Holding a PhD in Medicine from Leiden University Medical Center and an MBA from Quantic School of Business, Margien blends deep scientific knowledge with strategic business insight to accelerate breakthrough innovations in healthcare.